ESR1 and breast carcinoma: A recent preclinical study of six ER + breast cancer cell lines and one related xenograft reported that [18F]FLT and [18F]ISO-1 might be useful as predictive biomarkers for ER + breast cancer treated with the combination palbociclib/fulvestrant.